BACKGROUND: Stimulant use disorder (StUD) and attention-deficit/hyperactivity disorder (ADHD) frequently co-occur. This comorbidity complicates treatment and worsens clinical outcomes. Despite the high prevalence, shared vulnerability and clinical relevance of this comorbidity, evidence on effective pharmacotherapies among individuals with this dual diagnosis remains limited.
